Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 63, Issue 9, 2014, Pages 1141-1148

  Tremblay, André J ^a,b   Lamarche, Benoît ^a   Deacon, Carolyn F ^c   Weisnagel, S John ^b   Couture, Patrick ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dipeptidyl peptidase 4; Inflammation; Sitagliptin; Type 2 diabetes

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PLACEBO; SITAGLIPTIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD SAMPLING; BODY MASS; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LOW GRADE INFLAMMATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

DIPEPTIDYL PEPTIDASE-4; INFLAMMATION; SITAGLIPTIN; TYPE 2 DIABETES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DOWN-REGULATION; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PHOSPHOLIPASES A2, SECRETORY; PYRAZINES; SOLUBILITY; TRIAZOLES;

EID: 84906219286     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.06.004     Document Type: Article

References (53)

1. J.A. Beckman, M.A. Creager, and P. Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
2. R. Ross Atherosclerosis-an inflammatory disease N Engl J Med 340 1999 115 126
3. A.D. Pradhan, J.E. Manson, and N. Rifai et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 2001 327 334
4. B. Thorand, H. Lowel, and A. Schneider et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998 Arch Intern Med 163 2003 93 99
5. A.R. Folsom, W.D. Rosamond, and E. Shahar et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators Circulation 100 1999 736 742
6. A.J. Grau, F. Buggle, and H. Becher et al. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases Thromb Res 82 1996 245 255
7. R. Shurtz-Swirski, S. Sela, and A.T. Herskovits et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients Diabetes Care 24 2001 104 110
8. P.M. Ridker, M. Cushman, and M.J. Stampfer et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
9. I.A.M. van den Oever, H.G. Raterman, and M.T. Nurmohamed et al. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus Mediators Inflamm 2010 2010 10.1155/2010/792393 [Article ID 792393, 15 pages]
10. G. Reaven Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning Circulation 112 2005 3030 3032
11. M.M. Combettes GLP-1 and type 2 diabetes: physiology and new clinical advances Curr Opin Pharmacol 6 2006 598 605
12. M.A. Nauck, N. Kleine, and C. Orskov et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744
13. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
14. H. Liu, A.E. Dear, and L.B. Knudsen et al. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules J Endocrinol 201 2009 59 66
15. T. Nystrom, M.K. Gutniak, and Q. Zhang et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab 287 2004 E1209 E1215
16. D. Kim, L. Wang, and M. Beconi et al. (2R)-4-oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 48 2005 141 151
17. G.A. Herman, A. Bergman, and C. Stevens et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes J Clin Endocrinol Metab 91 2006 4612 4619
18. G.A. Herman, C. Stevens, and K. Van Dyck et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin Pharmacol Ther 78 2005 675 688
19. R.J. Havel, H. Eder, and J. Bragdon The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J Clin Invest 34 1955 1345 1353
20. J.J. Albers, G.R. Warnick, and D. Wiebe et al. Multi-laboratory comparison of three heparin-Mn2 + precipitation procedures for estimating cholesterol in high-density lipoprotein Clin Chem 24 1978 853 856
21. M. Kinoshita, M. Kojima, and T. Matsushima et al. Determination of apolipoprotein B-48 in serum by a sandwich ELISA Clin Chim Acta 351 2005 115 120
22. A.J. Tremblay, B. Lamarche, and C.F. Deacon et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes Diabetes Obes Metab 13 2011 366 373
23. T.B. Ledue, D.L. Weiner, and J.D. Sipe et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum Ann Clin Biochem 35 Pt 6 1998 745 753
24. M.Y. Donath, D.M. Schumann, and M. Faulenbach et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy Diabetes Care 31 Suppl. 2 2008 S161 S164
25. K.E. Wellen, and G.S. Hotamisligil Inflammation, stress, and diabetes J Clin Invest 115 2005 1111 1119
26. J.A. Ehses, H. Ellingsgaard, and M. Boni-Schnetzler et al. Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction Arch Physiol Biochem 115 2009 240 247
27. S.E. Shoelson, J. Lee, and A.B. Goldfine Inflammation and insulin resistance J Clin Invest 116 2006 1793 1801
28. A.D. Dobrian, Q. Ma, and J.W. Lindsay et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice Am J Physiol Endocrinol Metab 300 2011 E410 E421
29. S. Devaraj, and I. Jialal Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway Cytokine 47 2009 6 10
30. L. Ferreira, E. Teixeira-de-Lemos, and F. Pinto et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) Mediators Inflamm 2010 2010 10.1155/2010/592760 [Article ID 592760, 11 pages]
31. S. Hattori Sitagliptin reduces albuminuria in patients with type 2 diabetes Endocr J 58 2011 69 73
32. N. Satoh-Asahara, Y. Sasaki, and H. Wada et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients Metabolism 62 2013 347 351
33. A. Makdissi, H. Ghanim, and M. Vora et al. Sitagliptin exerts an antinflammatory action J Clin Endocrinol Metab 97 2012 3333 3341
34. G. Derosa, A. Carbone, and A. D'Angelo et al. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin Intern Med 52 2013 2179 2187
35. T. Roth, F. Podesta, and M.A. Stepp et al. Integrin overexpression induced by high glucose and by human diabetes: potential pathway to cell dysfunction in diabetic microangiopathy Proc Natl Acad Sci U S A 90 1993 9640 9644
36. H. Taki, A. Kashiwagi, and Y. Tanaka et al. Expression of intercellular adhesion molecules 1 (ICAM-1) via an osmotic effect in human umbilical vein endothelial cells exposed to high glucose medium Life Sci 58 1996 1713 1721
37. M. Shimabukuro, N. Higa, and I. Chinen et al. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study J Clin Endocrinol Metab 91 2006 837 842
38. T.C. Wascher, I. Schmoelzer, and A. Wiegratz et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance Eur J Clin Invest 35 2005 551 557
39. H. Liu, Y. Hu, and R.W. Simpson et al. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression J Endocrinol 196 2008 57 65
40. M. Arakawa, T. Mita, and K. Azuma et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4 Diabetes 59 2010 1030 1037
41. M. Nagashima, T. Watanabe, and M. Terasaki et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice Diabetologia 54 2011 2649 2659
42. Q. Zhong, R.J. Bollag, and D.T. Dransfield et al. Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells Peptides 21 2000 1427 1432
43. Y. Nogi, M. Nagashima, and M. Terasaki et al. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice PLoS One 7 2012 10.1371/journal.pone.0035683 [article ID e35683; 8 pages]
44. G.D. Norata, L. Grigore, and S. Raselli et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies Atherosclerosis 193 2007 321 327
45. C. Verseyden, S. Meijssen, and M.C. Cabezas Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia J Clin Endocrinol Metab 89 2004 5021 5029
46. A. Alipour, J.W. Elte, and H.C. van Zaanen et al. Postprandial inflammation and endothelial dysfuction Biochem Soc Trans 35 2007 466 469
47. A.J. van Oostrom, J. van Wijk, and M.C. Cabezas Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis Drugs 64 Suppl. 2 2004 19 41
48. M. Kimura-Matsumoto, Y. Ishikawa, and K. Komiyama et al. Expression of secretory phospholipase A2s in human atherosclerosis development Atherosclerosis 196 2008 81 91
49. I.J. Hatoum, F.B. Hu, and J.J. Nelson et al. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes Diabetes 59 2010 1239 1243
50. D. Divchev, and B. Schieffer The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis? Vasc Health Risk Manag 4 2008 597 604
51. A. Zalewski, and C. Macphee Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target Arterioscler Thromb Vasc Biol 25 2005 923 931
52. M. Kohno, K. Yokokawa, and K. Yasunari et al. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration Circulation 98 1998 353 359
53. Y. Rikitake, K. Hirata, and S. Kawashima et al. Inhibition of endothelium-dependent arterial relaxation by oxidized phosphatidylcholine Atherosclerosis 152 2000 79 87